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In seropositive individuals Epstein–Barr virus (EBV)
establishes a virus reservoir in peripheral blood
lymphocytes (PBLs). Transmission from one indi-
vidual to another occurs via saliva due to a lytic
(virion productive) phase of infection in the
oropharynx. EBNA-1 is responsible for maintaining
viral episomes in the host cell and could, therefore,
also affect the persistence of the virus in different
cell lineages. Based on sequence analysis of EBNA-
1 we now demonstrate that (i) in addition to the
prototype EBNA-1 (identical to the B95.8 virus
EBNA-1), EBV in normal individuals encompasses
multiple EBNA-1 subtypes, both in PBLs and in oral
Introduction
Epstein–Barr virus (EBV) infects about 90% of the world’s
population (Klein, 1994). In normal seropositive individuals
EBV maintains a reservoir in circulating B cells, in which EBV
replication is severely restricted. EBV is transmitted pre-
dominantly in saliva, and viral particles are readily detected in
oral secretions (OS) (Yao et al., 1985). The existence of
preferentially replicative and latent virus strains has never been
demonstrated and it must be presumed that EBV enters a lytic
cycle in lymphocytes within lymphoid tissue in the pharynx, or
after infection of pharyngeal epithelial cells (Miller, 1990 ;
Allday & Crawford, 1988). Recently, two groups have been
unable to demonstrate the presence of EBV in pharyngeal
epithelial cells in normal individuals or patients with infectious
mononucleosis by in situ hybridization [using Epstein–Barr
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secretions; (ii) although EBV with prototype EBNA-
1 is the predominant virus in normal individuals, it is
very rarely associated with either nasopharyngeal
carcinoma (NPC) or Burkitt’s lymphoma (BL) ; (iii)
EBV with an EBNA-1 subtype (V-val) frequently
associated with NPC is also selectively detected in
oral secretions and not in PBLs; (iv) EBV with the
EBNA-1 subtype V-pro is restricted to PBLs, while a
mutated version of this subtype is present in BL, but
not in NPC. These findings suggest that the
variations in EBNA-1 may be relevant to the ability
of EBV to persist in different cell types, and hence
relevant to its oncogenic potential.
virus-encoded RNA (EBER) to detect latently infected cells]
(Anagnostopoulos et al., 1995 ; Tao et al., 1995). However,
transient (lytic infection) or a low incidence of infection of
normal epithelial cells cannot be ruled out, and EBV is clearly
capable of infecting epithelial cells in some circumstances
(Knox et al., 1996).
EBV is also associated with a broad range of human
malignancies including Burkitt’s lymphoma (BL) (Magrath
et al., 1993) and nasopharyngeal carcinoma (NPC) (zur Hausen
et al., 1970). In recent reports we and others have described
several variants of EBNA-1 relative to the prototype virus
B95.8 (Bhatia et al., 1996 ; Wrightham et al., 1995 ; Snudden et
al., 1995). Each of these EBNA-1 variants has been identified as
the exclusive virus subtype in tumour biopsies and}or tumour
or lymphoblastoid cell lines known to carry monoclonal EBV,
strongly suggesting that these variants represent distinct virus
subtypes. We have, therefore, classified EBV into five subtypes,
based on the EBNA-1 sequence in the carboxy-terminal region,
which we have named according to the amino acid at position
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Fig. 1. Partial amino acid sequences of the region spanning amino acids
469–530 in the carboxy terminus of EBNA-1 in the various subtypes of
EBV. Changes with respect to the prototype B95.8 sequence are shown in
bold type.
487 in EBNA-1, since this amino acid residue is highly
predictive of the pattern of mutations observed (Fig. 1). We
have called two of the subtypes ‘prototypes ’. One is P-ala,
whose EBNA-1 sequence is identical to that of the B95.8-
derived virus, and the second, P-thr, differs slightly from the
B95.8 sequence (P-ala) in the carboxy-terminal region. We
have referred to the three other subtypes as ‘variants ’ (V-pro,
V-leu and V-val) because they differ more markedly from P-ala
than does P-thr. Snudden et al. (1995) identified the EBNA-1
subtype we have referred to as V-val in NPC biopsies, but their
report does not indicate whether this subtype is specific to
tumour cells in such patients and does not provide information
on the frequency of the variant EBNA-1 subtypes in NPC.
To date, EBNA-1 subtypes have not been studied in saliva.
In our previous report (Bhatia et al., 1996), we were unable to
identify V-val in peripheral blood lymphocytes (PBLs). We
have, therefore, examined sequence variations in EBNA-1 in
saliva and peripheral blood in 21 individuals to determine
whether the V-val subtype can be detected among virus
particles released by cells present in the pharynx or salivary
glands. In addition, we have examined NPC and BL, as well as
PBLs, from various geographical regions.
Methods
+ Tumour samples. DNA from NPC tumour tissue was obtained
from patients presenting at the Faculty of Medicine, University of Hong
Kong and Institut Gustave Roussy, France. DNA from BLs was extracted
from frozen biopsies and cell lines from Africa, South America and USA.
+ Normal samples. Twenty ml of heparinized peripheral blood was
obtained from 53 normal seropositive individuals and PBLs were isolated
using Ficoll–Hypaque density gradient centrifugation. OS from 21 of
these individuals, obtained by gargling for 2 min with 10 ml phosphate-
buffered saline, were also examined. The mouth washes were lyophilized
and the residual material used for DNA extraction by cell lysis and
digestion with proteinase K according to standard techniques.
The EBNA-1 genotype was determined by PCR and direct sequence
analysis of the PCR product as described previously. For at least one of
each of the individual subtypes, in addition to the direct sequencing,
sequence information was confirmed by plasmid sequencing after cloning
the amplified products in a TA vector (Invitrogen).
Results
Pattern of EBNA-1 subtypes in peripheral blood
lymphocytes and lymphoblastoid lines from healthy
individuals
We have previously reported sequence variations in the
carboxy region of EBNA-1 from EBV in PBLs from 32 healthy
individuals. The sequence of EBNA-1 in 14 of these 32
individuals was homogeneous (either P-ala or P-thr), whereas
18 individuals demonstrated sequence heterogeneity with
multiple bands at the same codon positions in sequencing gels,
indicating the presence of a mixture of EBNA-1 subtypes.
Based upon the codons in which variations were observed, the
presence of specific subtypes in the mixtures could be readily
discerned (Bhatia et al., 1996). In the DNA samples obtained
from PBLs from an additional 21 healthy individuals, we have
now detected the same three EBV subtypes, P-ala, P-thr and V-
pro (see Fig. 1 for sequence differences among the subtypes),
and again, more than half of the test subjects (13}21) carried
EBV with multiple EBNA-1 subtypes (Table 1). The compiled
results from the two studies show that the prototype P-ala was
the most frequent EBV subtype observed in PBLs, being
present in 75% of normal individuals (40}53). The P-thr and V-
pro subtypes were detected in 29 (55%) and 21 (40%) normal
individuals, respectively. More than half of the test subjects
(31}53) were infected with multiple EBV subtypes, the
remaining 22 carried either P-ala (10) or P-thr (12). P-ala and
P-thr were both detected in 10 subjects. Of considerable
interest was the observation that V-pro (readily apparent
because of additional amino acid substitutions, for example
codons 471, 480 and 500 ; see Fig. 1) was never detected in
isolation, but only in the presence of one of the prototype
EBNA-1s, either P-ala (14), P-thr (1) or both (6). V-leu, which
we previously detected in BL, and V-val, reported previously
by Snudden et al. (1995) in NPC, were not detected in any of
the samples. There was no apparent difference in the patterns
Table 1. Distribution of EBNA-1 subtypes in matched
peripheral blood lymphocytes and oral secretions from
21 test subjects
EBNA-1 subtype (no. of individuals)
PBL OS
P-ala (6) P-ala (5)
P-ala­V-val (1)
P-thr (2) P-thr (2)
P-ala­P-thr (8) P-ala­P-thr (4)
P-ala­P-thr­V-val (4)
P-ala­V-pro (4) P-ala (4)
P-ala­P-thr­V-pro (1) P-ala­P-thr (1)
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Carboxy terminus
Fig. 2. Examples of sequencing data representing part of the carboxy terminus obtained from sequencing of EBNA-1-amplified
DNA from oral samples with various subtypes of EBV. The two panels on the right illustrate direct sequencing reactions of
samples with mixtures of (i) P-ala, P-thr and V-val ; (ii) P-ala and V-val ; and (iii) P-ala and P-thr. The three panels on the left
illustrate sequencing data from subcloned PCR products obtained from the amplification of EBNA-1 from oral samples. Base
changes with reference to prototype EBNA-1 (P-ala) and the occurrence of multiple bases are shown in bold type and indicated
by arrowheads.
of EBNA-1 variants in lymphocytes obtained from individuals
in the USA (40), Nigeria (6) or South America (7).
We have also examined 26 spontaneously derived lympho-
blastoid cell lines (LCLs) and have not been able to detect
either V-pro or V-val in any ; P-ala was detected in 10 and P-
thr in 16 of these cell lines. In each LCL only a single subtype
was present.
EBV with the V-val EBNA-1 subtype is detected in oral
secretions from healthy individuals
Since the major route of transmission of EBV is via OS, we
sequenced the EBNA-1 carboxy region of EBV from the saliva
of 21 of the individuals whose PBLs we had examined. As with
PBLs, nucleotide sequences were consistent with the presence
of one or more EBNA-1 subtypes in each sample. There was
general concordance between EBV subtypes present in PBLs
and those detected in the oropharyngeal secretions (Table 1)
with two significant exceptions : (i) individuals who carried the
V-pro subtype in their PBLs did not show the presence of this
subtype in OS and (ii) the V-val subtype was detected in the
throat washings of five (24%) of these subjects whose
lymphocytes contained either P-ala alone or P-ala and P-thr
(Fig. 2 and Table 1). In none of these five subjects was V-val
detectable in simultaneously obtained PBLs. All OS samples in
which V-val was detected were obtained from subjects in the
USA.
V-val EBNA-1 from normal oral secretions carries
substitutions in the amino-terminal region identical to
those in the V-val identified in NPC biopsies
Analysis of the amino terminus of EBNA-1 by Snudden et
al. (1995) indicated that the EBNA-1 subtypes identified in
NPCs also contained changes at amino acids 16 (Glu-Gln), 18
(Gly-Glu), 20 (Thr-Ser), 24 (Glu-Asp) and 27 (Gly-Ser)
compared to P-ala EBNA-1. It was apparent from their data
that the substitutions at amino acids 16 and 18 were common
to both the EBNA-1 subtypes we designated V-val and P-thr,
but the change at amino acid 20 (Thr-Ser) was unique to the V-
val subtype and the changes at amino acids 24 (Glu-Asp) and
27 (Gly-Ser) were only present in the single P-thr subtype they
described.
In the absence of normal cell lines or virus isolates from
normal cells that contain the V-val EBNA-1, analysis of
concordance between the amino-terminal and the carboxy-
terminal substitutions for this subtype can only be performed
BGGF
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Amino terminus
Fig. 3. Sequence data from the amino-terminal region of EBNA-1 in OS
samples. Amino-terminal region of EBNA-1 was amplified from DNA
obtained from OS and the amplified products were directly sequenced.
Panel on the left is a sequence from two of the three OS samples that
contained a mixture of substitutions in the amino terminus typical of P-thr
and V-val (see Fig. 4). For comparison, the amino-terminal sequence of
EBNA-1 in PBLs with the P-ala subtype is given in the right-hand panel.
Substitutions and heterogeneity are shown in bold type and indicated with
arrowheads.
in OS samples that contain mixed EBNA-1 subtypes. Fur-
thermore, the presence of an Ala-Gly repeat region between
the amino terminus and the carboxy terminus prevents efficient
amplification of the complete region as a single DNA fragment.
We therefore sequenced a DNA fragment from nucleotide
®9 (relative to A of ATG) to nucleotide 270, spanning the
entire amino-terminal region of EBNA-1 in saliva from healthy
individuals. Examination of these data demonstrated sub-
stitutions at amino acids 16, 18, 20, 24 and 27 in several OS
samples (Figs 3 and 4). However, the variation at amino acid 20
(Thr-Ser), which was characteristic of the V-val subtype seen in
NPCs, was observed in only four of the five OS samples which,
in addition to other substitutions, also contained valine at
position 487.
Substitutions at codons 24 and 27 occur in samples
that carry a P-thr subtype EBNA-1
We wished to determine whether the substitutions at
codons 24 and 27 reported by Snudden et al. (1995) in the
EBNA-1 from the C-15 cell line derived from NPC were
always concordant with the presence of P-thr in the carboxy
terminus. We hence sequenced the amino terminus of EBNA-
Fig. 4. Correlation of amino acid substitutions in the amino-terminal region
of EBNA-1 (residues 16–28) with substitutions in the carboxy region that
define the EBNA-1 subtype (P-ala, P-thr, V-pro and V-val) in EBV genomes
present in normal PBLs, OS samples or in spontaneously derived LCLs.
The amino acid substitutions are derived from DNA-based sequence
analysis. Where DNA sequence analysis indicated the presence of
heterozygous nucleotides, alternative amino acids are shown at the same
position.
1 from eight PBLs (five of which contained P-thr) and nine OS
(eight of which contained P-thr) samples (Fig. 4). Of the eight
(four PBLs and four OS) samples that carried the characteristic
substitutions at amino acids 24 and 27, the carboxy region of
EBNA-1 in seven was consistent with the P-thr subtype.
Another six samples that contained P-thr (five OS and one
PBLs) did not carry the substitutions at codons 24 and 27. We
next sequenced the amino-terminal region in 13 spontaneous
LCLs that were established from PBLs of two individuals in
which we had determined the carboxy region of EBNA-1 to be
identical to the P-thr subtype ; we found that the substitutions
at codons 24 and 27 were present in all 13 spontaneous LCLs
(Fig. 4). Thus, the substitutions at amino acids 24 and 27
occurred preferentially in association with the P-thr subtype
EBV.
PCR products obtained by amplification of the amino
terminus from two independent OS samples (V-val and P-thr)
and two LCLs that contained P-thr were cloned in a TA vector
and the inserts from subcloned plasmids were independently
BGGG
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Fig. 5. The panel on the right depicts
amino-terminal EBNA-1 fragments from
OS samples shown in Fig. 3 that were
subcloned following PCR amplification
and independently sequenced. The panel
on the left shows sequencing data
obtained from the subcloned P-ala
fragment shown in Fig. 3. Substitutions
are shown in bold type and indicated by
arrowheads.
sequenced. These data, shown in Fig. 5, demonstrated that the
subclones contained only the substitutions at amino acids 16,
18 and 20 (i.e. as found in V-val from NPC), or the substitutions
at amino acids 16, 18, 24 and 27 (i.e. as in P-thr from BL or
NPC) or contained no substitutions. None of the subclones
contained a subset or an admixture of the prototype and the
two sets of substitutions.
Prototype EBNA-1 is rarely detected in
EBV-associated tumours
Table 2 is a summary of carboxy- and amino-terminal
EBNA-1 sequences from BL and NPC tumours. In every case,
only a single subtype was observed in each tumour (i.e. in no
case were multiple bands present at the same position),
whether BL or NPC. V-leu was present only in the BL samples
and V-val only in the NPCs. All 14 BL samples that were typed
as P-thr with respect to the carboxy terminus also contained
the concordant substitutions at the amino terminus. Only one
of the two P-ala-containing tumours was truly prototype in
both the amino and carboxy regions. The other contained an
amino terminus consistent with P-thr. Of 11 V-leu samples,
eight contained amino-terminal sequences typical of P-ala and
three contained the substitutions at amino acids 24 and 27,
typical of P-thr. None of the BL samples contained amino-
terminal substitutions found in NPCs or OS containing V-val.
Of 13 NPC samples that were analysed for EBNA-1 sequences
in both the carboxy and amino termini, nine samples were
typically V-val in both the regions, three samples were
identical to P-thr and one sample contained a carboxy region
Table 2. EBNA-1 carboxy- and amino-terminal variations
in tumours
Tumour
samples
Carboxy
region
Amino
region
Burkitt’s lymphoma
1 P-ala P-ala
1 P-ala P-thr
14 P-thr P-thr
1 V-pro P-ala
8 V-leu P-ala
3 V-leu P-thr
Nasopharyngeal carcinoma
9 V-val V-val
3 P-thr P-thr
1 P-thr P-ala
identical to P-thr and amino-terminal sequences identical to P-
ala. None of the NPC samples contained either V-leu or V-pro.
Thus, only one (a BL from North Africa) of the 41 tumour
samples examined contained a true prototype (P-ala) EBNA-1.
Discussion
Traditionally, EBV has been divided into type I and type II
strains. These strains are based upon sequence variations in
EBNA-2 and EBNAs 3A, 3B and 3C (Adldinger et al., 1985 ;
Sculley et al., 1989 ; Rowe et al., 1989 ; Sample et al., 1990).
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Most isolates of EBV are type I, but type II virus was reported,
in a study from Memphis, USA, to be frequently found in OS
(Sixbey et al., 1989). Type II EBV has been shown to be present
in 40–50% of EBV-associated endemic BL and AIDS-associated
lymphomas and lymphomas in the immune-compromised host
(Goldschmidts et al., 1992 ; Boyle et al., 1991). Recently, we and
others have described variations in the EBNA-1 sequence (Fig.
1) in EBV isolates from tumours and spontaneously derived
LCLs (Bhatia et al., 1996 ; Snudden et al., 1995 ; Wrightham et
al., 1995). These variations occur with equal frequency in type
I and type II strains (Bhatia et al., 1996 ; Wrightham et al., 1995).
The detection of each of the EBNA-1 subtypes as the sole
species of EBNA-1 in either tumour samples or immortalized
cell lines indicates that each subtype exists as a separate
subspecies. Thus, the simultaneous presence in some PBLs and
OS samples of clusters of substitutions typical of more than
one EBNA-1 subtype strongly suggests that multiple virus
subtypes are present in the blood and saliva of a high fraction
of normal individuals. This interpretation is further supported
by the patterns of substitutions observed in the subcloned
inserts from the amplified PCR products (Figs 2 and 4). Each
clone contained an EBNA-1 sequence pattern identical to that
observed in tumours or cell lines containing a single EBNA-1
subtype. Finally, there is concordance in the substitutions in
the amino and the carboxy regions in that the amino region
patterns typical of one or the other subtype (e.g. P-thr, V-val)
were usually found only in the presence of the expected
carboxy region pattern. Substitutions at amino acid 20 appear
to be specific for the V-val subtype, and were observed only in
OS samples and in NPCs from Hong Kong, whereas
substitutions at codons 24 and 27 occurred for the most part in
the presence of a threonine at position 487. An exception to
this was observed in BL, where a V-leu carboxy terminus was
associated either with a B95.8-like amino terminus or the
changes in codons 24 and 27 associated in normal cells and
NPCs with threonine at codon 487.
Our data are entirely consistent with the possibility that
the distinctive set of substitutions observed by us and Snudden
et al. (1995) in NPC from Hong Kong, which we have referred
to as the V-val subtype of EBNA-1, is derived from a virus
subtype that is detectable in OS of normal individuals but does
not appear to be present in normal lymphocytes. This
complements our previous observation (Bhatia et al., 1996 ;
extended in the present report) that BL is frequently associated
with an EBNA-1 subtype not found either in normal
lymphocytes or OS, although a subset of NPCs and BLs from
North Africa carry the P-thr subtype found in both PBLs and
throat washings.
There are two possibilities that could account for our
finding that multiple viral subtypes (based upon EBNA-1
sequences) are present in the same individual. Either the
subtypes arise from a single subtype (that which originally
infected the individual) by an ordered and incremental process
of substitutions, a phenomenon that has been documented in
the generation of other mutant viruses (Molla et al., 1996) or
the subtypes exist as naturally occurring virus subtypes. The
latter possibility would require the additional corollary that
individuals may be infected by more than one subtype and,
moreover, that certain subtypes (V-pro and V-val) can only
infect individuals already infected with P-ala or P-thr. This
seems inherently unlikely since (i) Ebnotyping is consistent
with infection and persistence of a single virus type and (ii)
multiple subtypes would presumably have to infect the same
cell if some are required to ‘help ’. This is not only contrary to
the current paradigms but would presumably be mediated
against by virtue of the very small number of EBV-containing
cells in normal individuals.
While at first sight the generation of multiple subtypes
from the original infecting virus also seems improbable, since
both V-pro and V-val differ consistently at multiple residues
from the P subtypes (Bhatia et al., 1996), we favour this
possibility as it has ample precedence in the well-described
quasi-species of RNA viruses (Duarte et al., 1994 ; Eigen, 1993).
Moreover our failure to detect, to date, V-pro in the LCLs
derived spontaneously from PBLs, and the similar absence of
this subtype in the cell lines examined by Wrightham et al.
(1995) suggest that V-pro is not capable of transforming B cells
and is therefore unlikely to be transmitted from one individual
to another. However, known transformation-defective variants
of EBV (for example P3HR1) are not V-pro. The apparent
absence of V-pro from saliva is entirely consistent with this
possibility, and further suggests that V-pro is also unable to
enter into a lytic cycle, although we cannot exclude the
possibility that V-pro is present in OS, but in numbers too
small to be detected.
The presence of V-val in saliva but not in PBLs also requires
an explanation. If epithelial cells do not normally contain EBV,
virus must presumably enter saliva from PBLs which enter a
lytic phase while passing through pharyngeal lymphoid tissue.
The absence of V-val in PBLs makes this an unlikely scenario
with respect to this subtype and the possibility that V-val is a
subtype particularly adapted to epithelial cells must be
considered. This is not inconsistent with the recent failure to
identify EBV in epithelial cells since (i) one of these studies was
conducted in infectious mononucleosis (IM) (if V-val is derived
from P-ala or P-thr in vivo it would be unlikely to be present in
primary infection) and (ii) if V-val were predominantly lytic
in epithelial cells it may prove to be difficult to detect.
Alternatively, it is possible that epithelial cells are only rarely
infected by V-val, or such cells fail to express EBERs. Either
explanation would account for the failure to detect EBV in
epithelial cells. One possible explanation for our observation
that V-val was detected only in association with P-ala or P-thr
or both is that the establishment of a reservoir in lymphocytes
is essential for the persistence of EBV in the host. Even if small
numbers of epithelial cells were infected by V-val transmitted
in saliva from another individual, lysis of such cells would lead
to rapid elimination of the infection. Thus, the presence of
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significant numbers of V-val particles in OS probably requires
continuous generation from P-ala or P-thr. The ability to detect
V-val may be indicative of a higher level of lytic infection in
the individual, but to examine this question, quantitative
assessment of virus in OS would be required. The presence of
V-val in saliva is quite consistent, of course, with its association
with NPC (Table 2 ; Snudden et al., 1995), and studies of the
frequency of V-val in OS in regions in which this disease is
prevalent and its association with other factors believed to
predispose to this disease (e.g. consumption of salted fish
during infancy) would be worthwhile. Further studies of
EBNA-1 subtypes in NPC from different world regions is also
warranted.
Although the prototype virus (P-ala) is the most prevalent
subtype and can be readily detected both in OS and in PBLs
from the majority of healthy individuals, it is rarely present in
EBV-positive BLs or NPCs. In addition to our data this finding
is further supported by the report of Snudden et al. (1995) and
Wrightham et al. (1995) who also described variations of
EBNA-1 in tumour samples. Wrightham et al. (1995) examined
five tumour cell lines from BLs, and P-ala was not present in
any of these samples. Snudden et al. (1995) described the
presence of V-val in biopsies from Chinese NPC and P-thr in
one NPC xenograft obtained from a North African patient, but
again did not observe P-ala in the material. It is possible that
this subtype cannot readily infect non-lymphoid cells ; how-
ever, this does not explain its absence in BLs. Our study of
EBNA-1 subtypes in BLs (USA, South America, Africa), normal
PBLs and OS (USA, South America, Africa) and NPCs (Hong
Kong and Africa) indicates that our findings cannot be simply
explained on the basis of the prevalence of the various EBNA-
1 subtypes in different geographic regions. P-ala EBNA-1 in
normal samples appears to be independent of geography, and
is absent in tumour samples from regions in which it is present
in the PBLs of 75% of normal individuals. Moreover in a
limited series of seven patients with either a P-thr or V-leu
EBNA-1 subtype in BL tissue, P-ala was readily detected in
spontaneous LCLs derived from the patients’ normal
lymphocytes (data not shown).
In conclusion, our data demonstrate the frequent co-
existence of multiple EBV subtypes, based on EBNA-1
sequences, in normal immunocompetent individuals and dem-
onstrate tropism of the V-pro and the V-val strains to
circulating lymphocytes (latent) and the oropharyngeal (lytic)
compartments respectively. The data also highlight the absence
of the prototype virus, P-ala, in both BL and NPC. One
subtype of EBNA-1, V-leu, which we have so far detected only
in BL, appears to be derived from V-pro by a single mutation
(Bhatia et al., 1996), but V-val, the subtype that we and
Snudden et al. (1995) have detected in NPC from Hong Kong,
is identical to an EBNA-1 subtype present in the saliva of
normal individuals from the USA. The observation that North
African BL and NPC are associated with the P-thr subtype of
EBNA-1 is intriguing, particularly since this subtype is
prevalent in PBLs in all regions we have examined to date. The
possibility that significant biological differences exist in the
tumours from North Africa must be considered. In the case of
BL, some support for this notion is provided by our previous
findings regarding regional differences in the pattern of
chromosomal breakpoint locations. An alternative explanation
is that regionally variable environmental or genetic factors
influence the oncogenicity of EBNA-1 subtypes.
Our findings suggest that either EBNA-1 influences the
virus life cycle, including cellular tropism, more than has been
previously conceived, or that EBNA-1 subtypes are associated
with genetic polymorphism in other genes that are responsible
for the differences we have observed. In either event, and
coupled to the predisposition of EBNA-1 transgenic mice to
lymphoma development (Wilson et al., 1996), our data provide
strong support for a direct role of EBNA-1 in human cancers.
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